Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Improved outcome of central nervous system germ cell tumors: implications for the role of risk-adapted intensive chemotherapy.

Yoo KH, Lee SH, Lee J, Sung KW, Jung HL, Koo HH, Lim DH, Kim JH, Shin HJ.

J Korean Med Sci. 2010 Mar;25(3):458-65. doi: 10.3346/jkms.2010.25.3.458. Epub 2010 Feb 17.

2.

[Treatment outcome of primary central nervous system germ cell tumors after combined therapy: a report of 23 cases].

Yang QY, Sun XF, Huang HQ, Zhen ZJ, Xia Y, Cai QQ, Ling JY.

Ai Zheng. 2008 Apr;27(4):438-41. Chinese.

PMID:
18423134
3.

The clinical characteristics and treatment outcome of 57 children and adolescents with primary central nervous system germ cell tumors.

Sun XF, Zhang F, Zhen ZJ, Yang QY, Xia YF, Wu SX, Zhu J, Lu SY, Wang J, Sun FF, Cai RQ, Chen Y, Li PF.

Chin J Cancer. 2014 Aug;33(8):395-401. doi: 10.5732/cjc.013.10112. Epub 2014 Jul 3.

4.

Primary chemotherapy for intracranial germ cell tumors: results of the third international CNS germ cell tumor study.

da Silva NS, Cappellano AM, Diez B, Cavalheiro S, Gardner S, Wisoff J, Kellie S, Parker R, Garvin J, Finlay J.

Pediatr Blood Cancer. 2010 Mar;54(3):377-83. doi: 10.1002/pbc.22381.

PMID:
20063410
5.

Treatment of primary CNS germinomatous germ cell tumors with chemotherapy prior to reduced dose whole ventricular and local boost irradiation.

Khatua S, Dhall G, O'Neil S, Jubran R, Villablanca JG, Marachelian A, Nastia A, Lavey R, Olch AJ, Gonzalez I, Gilles F, Nelson M, Panigrahy A, McComb G, Krieger M, Fan J, Sposto R, Finlay JL.

Pediatr Blood Cancer. 2010 Jul 15;55(1):42-6. doi: 10.1002/pbc.22468.

PMID:
20222020
6.

Malignant sacrococcygeal germ cell tumors in children: a 30-year experience from a single institution.

Büyükpamukçu M, Varan A, Küpeli S, Ekinci S, Yalcin S, Kale G, Yalçin B, Kutluk T, Akyüz C.

Tumori. 2013 Jan-Feb;99(1):51-6. doi: 10.1700/1248.13788.

PMID:
23549000
7.

Myeloablative chemotherapy and autologous stem cell transplantation in patients with relapsed or progressed central nervous system germ cell tumors: results of Korean Society of Pediatric Neuro-Oncology (KSPNO) S-053 study.

Baek HJ, Park HJ, Sung KW, Lee SH, Han JW, Koh KN, Im HJ, Kang HJ, Park KD.

J Neurooncol. 2013 Sep;114(3):329-38. doi: 10.1007/s11060-013-1188-1. Epub 2013 Jul 4.

PMID:
23824533
8.
9.

Multimodality therapy for CNS mixed malignant germ cell tumors (MMGCT): results of a phase II multi-institutional study.

Robertson PL, Jakacki R, Hukin J, Siffert J, Allen JC.

J Neurooncol. 2014 May;118(1):93-100. doi: 10.1007/s11060-013-1306-0. Epub 2014 Apr 4.

PMID:
24700239
10.

Phase II trial of high-dose carboplatin and etoposide with autologous bone marrow transplantation in first-line therapy for patients with poor-risk germ cell tumors.

Motzer RJ, Mazumdar M, Gulati SC, Bajorin DF, Lyn P, Vlamis V, Bosl GJ.

J Natl Cancer Inst. 1993 Nov 17;85(22):1828-35.

PMID:
7693955
11.

Primary chemotherapy for intracranial nongerminomatous germ cell tumors: results of the second international CNS germ cell study group protocol.

Kellie SJ, Boyce H, Dunkel IJ, Diez B, Rosenblum M, Brualdi L, Finlay JL.

J Clin Oncol. 2004 Mar 1;22(5):846-53.

PMID:
14990640
12.

Secreting germ cell tumors of the central nervous system (CNS). First results of the cooperative German/Italian pilot study (CNS sGCT).

Calaminus G, Andreussi L, Garré ML, Kortmann RD, Schober R, Göbel U.

Klin Padiatr. 1997 Jul-Aug;209(4):222-7.

PMID:
9293454
13.

Treatment results and prognostic factors for intracranial nongerminomatous germ cell tumors: single institute experience.

Lai IC, Wong TT, Shiau CY, Hu YW, Ho DM, Chang KP, Guo WY, Chang FC, Liang ML, Lee YY, Chen HH, Yen SH, Chen YW.

Childs Nerv Syst. 2015 May;31(5):683-91. doi: 10.1007/s00381-015-2623-8. Epub 2015 Mar 8.

PMID:
25749900
14.

Randomized comparison of combination chemotherapy with etoposide, bleomycin, and either high-dose or standard-dose cisplatin in children and adolescents with high-risk malignant germ cell tumors: a pediatric intergroup study--Pediatric Oncology Group 9049 and Children's Cancer Group 8882.

Cushing B, Giller R, Cullen JW, Marina NM, Lauer SJ, Olson TA, Rogers PC, Colombani P, Rescorla F, Billmire DF, Vinocur CD, Hawkins EP, Davis MM, Perlman EJ, London WB, Castleberry RP; Pediatric Oncology Group 9049; Children's Cancer Group 8882.

J Clin Oncol. 2004 Jul 1;22(13):2691-700.

PMID:
15226336
15.

A randomised phase 2 trial of intensive induction chemotherapy (CBOP/BEP) and standard BEP in poor-prognosis germ cell tumours (MRC TE23, CRUK 05/014, ISRCTN 53643604).

Huddart RA, Gabe R, Cafferty FH, Pollock P, White JD, Shamash J, Cullen MH, Stenning SP; TE23 Trial Management Group and Collaborators; National Cancer Research Institute Testis Cancer Clinical Studies Group.

Eur Urol. 2015 Mar;67(3):534-43. doi: 10.1016/j.eururo.2014.06.034. Epub 2014 Jul 4.

16.
18.

The impact of bleomycin on retroperitoneal histology at post-chemotherapy retroperitoneal lymph node dissection of good risk germ cell tumors.

Cary KC, Pedrosa JA, Kaimakliotis HZ, Masterson TA, Einhorn LH, Foster RS.

J Urol. 2015 Feb;193(2):507-12. doi: 10.1016/j.juro.2014.09.090. Epub 2014 Sep 22.

PMID:
25254937
19.

Personalised chemotherapy based on tumour marker decline in poor prognosis germ-cell tumours (GETUG 13): a phase 3, multicentre, randomised trial.

Fizazi K, Pagliaro L, Laplanche A, Fléchon A, Mardiak J, Geoffrois L, Kerbrat P, Chevreau C, Delva R, Rolland F, Theodore C, Roubaud G, Gravis G, Eymard JC, Malhaire JP, Linassier C, Habibian M, Martin AL, Journeau F, Reckova M, Logothetis C, Culine S.

Lancet Oncol. 2014 Dec;15(13):1442-50. doi: 10.1016/S1470-2045(14)70490-5. Epub 2014 Nov 13.

20.

The United Kingdom Children's Cancer Study Group's second germ cell tumor study: carboplatin, etoposide, and bleomycin are effective treatment for children with malignant extracranial germ cell tumors, with acceptable toxicity.

Mann JR, Raafat F, Robinson K, Imeson J, Gornall P, Sokal M, Gray E, McKeever P, Hale J, Bailey S, Oakhill A.

J Clin Oncol. 2000 Nov 15;18(22):3809-18.

PMID:
11078494

Supplemental Content

Support Center